All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Coagulase-negative staphylococci (CoNS) have come to be recognized as important, commonly isolated pathogens \[[@pone.0125818.ref001],[@pone.0125818.ref002]\]. Infections are usually associated with healthcare settings and occur in patients harbouring indwelling polymer or metallic devices \[[@pone.0125818.ref003]\]. CoNS cause \>10% of all infective endocarditis (IE) cases \[[@pone.0125818.ref004]\] and are among the most frequent etiological agents of intracardiac prosthetic device infections, such as prosthetic valve endocarditis (PVE) and intracardiac device (ICD) endocarditis \[[@pone.0125818.ref005]--[@pone.0125818.ref007]\]. In addition, these microorganisms are becoming an important cause of native valve endocarditis (NVE) \[[@pone.0125818.ref008]\]. Among CoNS species, *Staphylococcus lugdunensis* is notable for its particular virulence \[[@pone.0125818.ref009]\].

Resistance to methicillin and other antibiotics is becoming more frequent among CoNS. A glycopeptide, such as vancomycin, is the recommended treatment for methicillin-resistant CoNS (MR-CoNS) NVE, while gentamicin and rifampin are typically added in PVE \[[@pone.0125818.ref010]\]. The emergence of CoNS with reduced susceptibility to vancomycin \[[@pone.0125818.ref003]\], together with the increasing prevalence of glycopeptide-intermediate *Staphylococcus epidermidis* (GISE) \[[@pone.0125818.ref011]\] and resistance to rifampin and gentamicin among methicillin-resistant *S*. *epidermidis* (MRSE), limits therapeutic options and warrants investigation of alternative bactericidal agents.

Among patients with *Staphylococcus aureus* bacteremia, increased vancomycin minimum inhibitory concentrations (MICs) have been associated with clinical failures \[[@pone.0125818.ref012]\], while vancomycin MICs \>1 μg/mL have been associated with higher mortality \[[@pone.0125818.ref013]\]. There currently are no data regarding the influence of vancomycin MIC on the outcome of CoNS IE.

This study aimed to characterize the epidemiology, clinical characteristics, and antibiotic susceptibility pattern of CoNS IE, and the influence of methicillin susceptibility and vancomycin MIC on outcomes.

Methods {#sec002}
=======

This prospective cohort study was performed in an urban tertiary care hospital with 850 beds in Barcelona, Spain. All consecutive CoNS IE patients seen from 1995 to 2008 were recorded in a database using a standardized case report form. Only patients with a definite diagnosis of IE \[[@pone.0125818.ref014]\] were included. All survivors were followed ≥1 year. The Ethics Committee of our institution gave its approval to perform the current study.

The variables analyzed, including age, gender, history of chronic disease, calendar year, right- vs. left-sided IE, type of endocarditis (NVE, PVE, or ICD-associated), place of acquisition (community-acquired, nosocomial, or non-nosocomial healthcare-associated) \[[@pone.0125818.ref015]\], clinical complications (heart failure, renal failure, or systemic emboli, including stroke), need for surgery, and in-hospital and 1-year mortality, have been previously defined \[[@pone.0125818.ref016]\].

Due to the duration of the study period, antimicrobial treatment for CoNS IE was given according to the 1995 (originally) and 2005 (later) American Heart Association (AHA) recommendations \[[@pone.0125818.ref010],[@pone.0125818.ref017]\], both of which recommend the same agents for CoNS IE. Methicillin-susceptible CoNS (MS-CoNS) IE was treated with cloxacillin, and MR-CoNS IE was treated with either vancomycin alone (NVE) or combined with other antibiotics (PVE or ICD IE). The decision of using monotherapy or combination was at the discretion of the treating physician and influenced by factors related to patient' clinical status (ie, renal function, drug allergy, potential drug interactions, comorbidity, age). Per guidelines of the time \[[@pone.0125818.ref010],[@pone.0125818.ref017]\], a vancomycin trough concentration of 10--15 μg/mL was targeted.

In order to analyze the impact of methicillin resistance and vancomycin MIC on outcomes, we divided patients into 3 groups: patients treated with cloxacillin for MS-CoNS IE (Group 1), vancomycin for CoNS with vancomycin MIC \<2 μg/mL (Group 2), or vancomycin for CoNS with vancomycin MIC ≥2 μg/mL (Group 3). In the event of polyclonal or polymicrobial CoNS IE, we categorized patients per the higher vancomycin MIC.

Identification of CoNS Isolates {#sec003}
-------------------------------

Isolates were stored at -80°C in skim milk. Isolates were identified using the API ID 32 Staph (bioMérieux, Marcy l\'Etoile, France). Species were divided into 4 groups: *S*. *epidermidis*, *S*. *lugdunensis*, other CoNS, and polymicrobial IE. Polymicrobial infections were caused by different CoNS isolates. Polyclonal CoNS infections were caused by ≥2 isolates of the same species with different antibiotic susceptibilities and each isolate was counted separately.

Antibiotic Susceptibility Testing {#sec004}
---------------------------------

Susceptibility was determined by Etest according to the manufacturer's recommendations (AB Biodisk-bioMérieux, Marcy l\'Etoile, France). Etest strips were purchased from bioMérieux (Madrid, Spain). The following antimicrobials were evaluated: penicillin, oxacillin, erythromycin, clindamycin, gentamicin, ciprofloxacin, cotrimoxazole, rifampin, vancomycin, teicoplanin, linezolid, and daptomycin. The latter 2 agents were tested retrospectively after they became available and with emerging data about the impact of elevated vancomycin MICs. *S*. *aureus* ATCC 29213 was used as the test control strain. For vancomycin, isolates were divided according to MIC (\<2 μg/mL or ≥2 μg/mL).

Statistical Analyses {#sec005}
--------------------

Categorical variables were summarized as percentages and compared using the Chi-square or Fisher's exact test. Continuous variables were summarized as mean and SD. The Mantel-Haenszel test for trend was used if there were significant differences in vancomycin MIC over time among the isolates. The Kaplan-Meier estimator was used for survival analysis, and curves were compared using the log-rank test. For logistic regression analysis, predictors with a *P*\<0.30 were included, and it was performed by a likelihood ratio-based backward exclusion method. A 2-sided *P*\<0.05 was considered to be statistically significant. All statistics were calculated with SPSS statistical package version 16.0 (SPSS, Inc., Chicago, IL, USA).

Results {#sec006}
=======

Clinical Characteristics of CoNS IE {#sec007}
-----------------------------------

There were 103 patients with CoNS IE during the study, representing 16% of the 620 IE cases diagnosed at our institution ([Fig 1](#pone.0125818.g001){ref-type="fig"}). Regarding the type of IE, 36 (35%) were ICD-associated, 31 (30%) were PVE, and 36 (35%) were NVE. Stored CoNS isolates were available for 88 patients, in whom 98 isolates were identified. Isolates could not be obtained in the others due to transfer from another institution.

![Patient disposition.\
Abbreviations: IE, infective endocarditis; NV, native valve; PV, prosthetic valve; CoNS, coagulase-negative staphylococci.](pone.0125818.g001){#pone.0125818.g001}

The clinical characteristics and outcomes of these 103 patients are summarized by type of endocarditis in [Table 1](#pone.0125818.t001){ref-type="table"}. The majority of infections were due to *S*. *epidermidis*, while the species was not identified in 15 (15%) patients. In 59 (57%) patients, isolates were susceptible to methicillin, with a lower rate in PVE (36%) compared with NVE (61%) or ICD IE (72%) (*P* = 0.009). The aortic valve was most commonly involved, but 13 (13%) patients had involvement of multiple valves. While vegetations were present in 82 (80%) patients, only 13 (13%) patients had evidence of systemic emboli. Median vegetation size was greatest in ICD IE (*P* = 0.007); perivalvular abscesses were most common among patients with PVE (*P*\<0.001). Sixty-six patients (64%) required surgery, including almost all patients with ICD IE. Mortality rates were similar within the NVE and PVE groups and lowest among patients with ICD IE (*P*\<0.001).

10.1371/journal.pone.0125818.t001

###### Clinical characteristics and outcome of 103 consecutive patients with IE due to CoNS, according to the type of endocarditis (1995--2008).

![](pone.0125818.t001){#pone.0125818.t001g}

                                                       NVE (N = 36)                                                       PVE (N = 31)   ICD IE (N = 36)   *P* value                                     
  ---------------------------------------------------- ------------------------------------------------------------------ -------------- ----------------- --------------------------------------------- ---------
  Mean age (SD), y                                                                                                        61.8 (16.7)    60.7 (11.3)       62.1 (19.4)                                   0.506
  Male gender                                                                                                             27 (75)        24 (77)           30 (83)                                       0.676
  Year of diagnosis                                                                                                                                                                                      0.560
                                                       1995--1999                                                         13 (36)        9 (29)            9 (25)                                        
                                                       2000--2004                                                         14 (39)        9 (29)            15 (42)                                       
                                                       2005--2008                                                         9 (25)         13 (42)           12 (33)                                       
  CoNS species[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                     0.400
                                                       *S*. *epidermidis*                                                 17 (47)        18 (58)           25 (69)                                       
                                                       *S*. *lugdunensis*                                                 4 (11)         2 (7)             5 (14)                                        
                                                       Other CoNS[^b^](#t001fn003){ref-type="table-fn"}                   4 (11)         4 (13)            3 (8)                                         
                                                       Polymicrobial                                                      4 (11)         1 (3)             1 (3)                                         
                                                       Unknown                                                            7 (20)         6 (19)            2 (6)                                         
  Methicillin susceptibility                                                                                              22 (61)        11 (36)           26 (72)                                       0.009
  Predisposing conditions and underlying diseases                                                                                                                                                        
                                                       Diabetes mellitus                                                  1 (3)          8 (26)            4 (11)                                        0.015
                                                       Chronic renal failure                                              4 (11)         2 (7)             1 (3)                                         0.386
                                                       Hemodialysis                                                       4 (11)         0                 0                                             0.034
                                                       History of cancer                                                  4 (11)         5 (16)            2 (6)                                         0.239
                                                       HIV infection                                                      1 (3)          0                 0                                             1.000
                                                       Chronic liver disease                                              9 (25)         3 (10)            2 (6)                                         0.036
                                                       Chronic lung disease                                               0              2 (7)             3 (8)                                         0.267
                                                       Transplantation                                                    1 (3)          0                 0                                             1.000
  Presumed mode of acquisition                                                                                                                                                                           0.004
                                                       Nosocomial                                                         11 (31)        4 (13)            6 (17)                                        
                                                       Non-nosocomial health care associated                              11 (31)        18 (58)           7 (19)                                        
                                                       Community acquired                                                 14 (39)        9 (29)            23 (64)                                       
  Valve involvement                                                                                                                                                                                      \<0.001
                                                       Aortic                                                             14 (39)        12 (39)           1 (3)[^c^](#t001fn004){ref-type="table-fn"}   
                                                       Mitral                                                             13 (36)        11 (36)           0                                             
                                                       Tricuspid                                                          1 (3)          1 (3)             3 (8)[^c^](#t001fn004){ref-type="table-fn"}   
                                                       PCM/ICD wire[^c^](#t001fn004){ref-type="table-fn"}                 0              0                 34 (94)                                       
                                                       Unknown                                                            1 (3)          1 (3)             0                                             
                                                       Mitral + aortic                                                    4 (11)         5 (16)            0                                             
                                                       Tricuspid + aortic                                                 2 (6)          0                 0                                             
                                                       Tricuspid + aortic + mitral                                        1 (3)          1 (3)             0                                             
  Echocardiographic findings                                                                                                                                                                             
                                                       Presence of vegetations                                            31 (86)        25 (81)           26 (72)                                       0.338
                                                       Vegetation size in mm, median (IQR)                                10 (7--15)     10 (6.5--15.5)    20 (10--25)                                   0.007
                                                       Perivalvular abscess                                               4 (11)         15 (48)           0                                             \<0.001
  Complications                                                                                                                                                                                          
                                                       Heart failure                                                      15 (42)        11 (36)           0                                             \<0.001
                                                       Renal failure                                                      20 (56)        18 (58)           4 (11)                                        \<0.001
                                                       Systemic emboli                                                    4 (11)         9 (29)            0                                             0.001
  Antibiotic treatment                                                                                                                                                                                   0.098
                                                       Cloxacillin alone                                                  1 (3)          1 (3)             6 (17)                                        
                                                       Cloxacillin in combination[^d^](#t001fn005){ref-type="table-fn"}   13 (36)        8 (26)            16 (44)                                       
                                                       Vancomycin alone                                                   4 (11)         5 (16)            3 (8)                                         
                                                       Vancomycin in combination[^c^](#t001fn004){ref-type="table-fn"}    15 (42)        16 (52)           11 (31)                                       
                                                       Other antibiotics[^e^](#t001fn006){ref-type="table-fn"}            3 (8)          1 (3)             0                                             
  Outcome                                                                                                                                                                                                
                                                       Surgical treatment                                                 11 (31)        22 (71)           33 (92)                                       \<0.001
                                                       In-hospital mortality                                              16 (44)        14 (45)           2 (6)                                         \<0.001
                                                       1-year mortality                                                   20 (56)        16 (52)           3 (8)                                         \<0.001

Unless otherwise noted, all values are shown as n (%). Abbreviations: CoNS, coagulase-negative staphylococci; HIV, human immunodeficiency virus; ICD, intracardiac device; IE, infective endocarditis; IQR, interquartile range; NVE, native valve endocarditis; PCM/ICD, pacemaker/implantable cardioverter-defibrillator; PVE, prosthetic valve endocarditis; SD, standard deviation.

^a^Only 88 patients had available isolates; these 88 patients served as the basis for the rest of the study (see [Fig 1](#pone.0125818.g001){ref-type="fig"}).

^b^ *S*. *hominis* (7), *S*. *capitis* (2), *S*. *schleiferi* (2).

^c^PCM/ICD wire endocarditis was associated with tricuspid vegetations in 3 patients and aortic vegetations in 1 case.

^d^Administration of a second antibiotic, with or without a third, together with cloxacillin or vancomycin for \>2 days.

^e^Two patients received teicoplanin, 1 received imipenem, and 1 received linezolid.

The clinical characteristics and outcomes of the 88 patients with available isolates are summarized by CoNS species in [S1 Table](#pone.0125818.s001){ref-type="supplementary-material"}. In-hospital and 1-year mortality rates were similar among groups but were highest among patients infected with *S*. *lugdunensis* (55% for both).

CoNS Identification and Antibiotic Susceptibility Patterns {#sec008}
----------------------------------------------------------

Ninety-eight isolates were identified in 88 patients: 70 *S*. *epidermidis* (71%), 11 *S*. *lugdunensis* (11%), 10 *S*. *hominis* (10%), and 7 other species ([S2 Table](#pone.0125818.s002){ref-type="supplementary-material"}). There were 6 and 4 patients with polymicrobial and polyclonal IE, respectively.

Susceptibility data are presented in [S2 Table](#pone.0125818.s002){ref-type="supplementary-material"}. Overall, 44% of the CoNS isolates were methicillin-resistant, including 51% of *S*. *epidermidis*. One-third of MRSE also were resistant to gentamicin, rifampin, and ciprofloxacin. All isolates of *S*. *lugdunensis* remained methicillin-susceptible.

Forty-two isolates had a vancomycin MIC ≥2 μg/mL (35 isolates at 2 μg/mL, 5 isolates at 3 μg/mL, and 2 isolates at 4 μg/mL). By species, 47% of the *S*. *epidermidis* isolates and 7% of other species (*P*\<0.001) had vancomycin MICs of 2 μg/mL. The clinical, microbiological and therapeutic characteristics, as well as the outcomes, of the 39 patients with strains with vancomycin MIC ≥2 μg/mL can be seen in [S3 Table](#pone.0125818.s003){ref-type="supplementary-material"}. Two *S*. *epidermidis* isolates (both with vancomycin MICs of 3 μg/mL) demonstrated intermediate resistance to teicoplanin (MIC 16 μg/mL). We did not find any isolates with intermediate susceptibility to vancomycin. Vancomycin MIC did not show a trend towards increase over time for overall CoNS isolates (*P* = 0.49) nor for *S*. *epidermidis* specifically (*P* = 0.25); this pattern did not change according to methicillin susceptibility. All isolates remained linezolid- and daptomycin-susceptible, but 1 strain each of *S*. *epidermidis* and *S*. *capitis* had daptomycin MICs of 1.5 μg/mL. Regarding other recommended antibiotics for PVE, we found that 14/31 (45%) of the CoNS isolates in patients with PVE were resistant to gentamicin, rifampin and/or ciprofloxacin.

Impact of Methicillin Susceptibility and Vancomycin MIC on Outcomes {#sec009}
-------------------------------------------------------------------

Three of the 88 patients were excluded from the assessment of outcome because they were not treated with either cloxacillin or vancomycin, but instead were treated with teicoplanin (2) and linezolid (1). Cloxacillin was used in 38 (45%) patients (Group 1), and vancomycin was used in 47 (55%). Twelve of these 47 (26%) patients with MS-CoNS were treated with vancomycin because of penicillin allergy (3) or medical decision (9). Of these 12 patients, 2 died (17%). Among patients treated with vancomycin, 27 (32%) had CoNS isolates with vancomycin MICs \<2 μg/mL (Group 2) and 20 (24%) had MICs ≥2 μg/mL (Group 3). The main clinical characteristics of the 3 groups are presented in [Table 2](#pone.0125818.t002){ref-type="table"}.

10.1371/journal.pone.0125818.t002

###### Clinical characteristics of 85 patients with CoNS IE according to treatment received (cloxacillin or vancomycin).[^a^](#t002fn002){ref-type="table-fn"}
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                                                                                                                          Treated with vancomycin                       
  ------------------------------------------------- ----------------------------------------------------- --------------- ------------------------- ------------------- -------
  Mean age, y                                                                                             68.5 (55--77)   66.0 (59--73.5)           60.5 (44.5--72.5)   0.182
  Male gender                                                                                             28 (74)         20 (74)                   17 (85)             0.645
  CoNS species                                                                                                                                                          0.471
                                                    *S*. *epidermidis*                                    22 (58)         19 (70)                   16 (80)             
                                                    *S*. *lugdunensis*                                    7 (18)          4 (15)                    0                   
                                                    Other                                                 6 (16)          3 (11)                    2 (10)              
                                                    Polymicrobial[^b^](#t002fn003){ref-type="table-fn"}   3 (8)           1 (4)                     2 (10)              
  Predisposing conditions and underlying diseases                                                                                                                       
                                                    Diabetes mellitus                                     3 (8)           3 (11)                    4 (20)              0.387
                                                    Chronic renal failure                                 2 (5)           2 (7)                     2 (10)              0.865
                                                    Hemodialysis                                          2 (5)           1 (4)                     0                   0.792
                                                    History of cancer                                     4 (11)          1 (4)                     4 (20)              0.184
                                                    HIV infection                                         0               1 (4)                     0                   0.553
                                                    Chronic liver disease                                 2 (5)           3 (11)                    5 (25)              0.090
                                                    Chronic lung disease                                  1 (3)           3 (11)                    0                   0.168
                                                    Transplantation                                       0               1 (4)                     1 (5)               0.500
                                                    History of IE                                         1 (3)           0                         1 (5)               0.713
  Presumed mode of acquisition                                                                                                                                          0.080
                                                    Nosocomial                                            5 (13)          7 (26)                    6 (30)              
                                                    Non-nosocomial healthcare associated                  11 (29)         8 (30)                    10 (50)             
                                                    Community acquired                                    22 (58)         12 (44)                   4 (20)              
  Type of endocarditis, n (%)                                                                                                                                           0.109
                                                    NV                                                    11 (29)         10 (37)                   7 (35)              
                                                    PV                                                    7 (18)          8 (30)                    9 (45)              
                                                    Pacemaker lead                                        20 (53)         9 (33)                    4 (20)              
  Valve involvement                                                                                                                                                     0.301
                                                    Aortic                                                6 (16)          9 (33)                    7 (35)              
                                                    Mitral                                                8 (21)          4 (15)                    4 (20)              
                                                    Tricuspid                                             0               0                         1 (5)               
                                                    PCM/ICD wire                                          20 (53)         9                         4 (20)              
                                                    Unknown                                               0               1 (4)                     1 (5)               
                                                    Mitral + aortic                                       4 (11)          2 (7)                     2 (10)              
                                                    Tricuspid + aortic                                    0               1 (4)                     0                   
                                                    Tricuspid + aortic + mitral                           0               1 (4)                     1 (5)               
  Echocardiogra-phic findings                                                                                                                                           
                                                    Presence of vegetations                               28 (74)         22 (82)                   18 (90)             0.350
                                                    Vegetation size in mm, median (IQR)                   10 (0--19)      10 (1--16)                8 (2.5--10)         0.881
                                                    Perivalvular abscess                                  5 (13)          5 (20)                    5 (26)              0.436
  Complications                                                                                                                                                         
                                                    Heart failure                                         9 (24)          9 (33)                    5 (25)              0.670
                                                    Renal failure                                         11 (29)         14 (52)                   10 (50)             0.129
                                                    Systemic emboli                                       3 (8)           1 (4)                     4 (20)              0.178
  Outcomes                                                                                                                                                              
                                                    Surgery                                               28 (74)         16 (59)                   12 (60)             0.394
                                                    In-hospital mortality                                 7 (18)          12 (44)                   10 (50)             0.021
                                                    1-year mortality                                      8 (21)          13 (48)                   13 (65)             0.003

Unless otherwise noted, all values are shown as n (%). Abbreviations: CoNS, coagulase-negative staphylococci; HIV, human immunodeficiency virus; IE, infective endocarditis; IQR, interquartile range; PCM/ICD, pacemaker/implantable cardioverter-defibrillator; MIC, minimum inhibitory concentration; NV, native valve; PV, prosthetic valve.

^a^Three out of the 88 patients did not receive either cloxacillin or vancomycin and were not included.

^b^ *S*. *hominis* (7), *S*. *capitis* (2), *S*. *schleiferi* (2).

In-hospital mortality was higher among those patients treated with vancomycin, regardless of vancomycin MIC, than in those treated with cloxacillin (47% vs 18%; *P* = 0.012). In-hospital mortality was 18%, 44%, and 50% for Groups 1, 2, and 3, respectively (*P* = 0.021), and 1-year mortality was 21%, 48%, and 65%, respectively (*P* = 0.003). Mortality was similar for patients treated with cloxacillin regardless of vancomycin MIC ([Fig 2](#pone.0125818.g002){ref-type="fig"}). Conversely, the highest mortality was among vancomycin-treated patients infected with CoNS isolates having vancomycin MICs ≥2 μg/mL (*P* = 0.007). One-year survival analysis according to the treatment received and vancomycin MIC is presented in [Fig 3](#pone.0125818.g003){ref-type="fig"}.

![One-year mortality according to antibiotic treatment and vancomycin MIC.\
One-year mortality among 85 patients with coagulase-negative staphylococci infective endocarditis, according to antibiotic therapy and vancomycin minimum inhibitory concentration (MIC).](pone.0125818.g002){#pone.0125818.g002}

![One-year survival analysis according to antibiotic therapy and vancomycin MIC.\
One-year survival analysis of 85 patients with coagulase-negative staphylococci infective endocarditis according to the treatment received and vancomycin minimum inhibitory concentration (MIC).](pone.0125818.g003){#pone.0125818.g003}

[Table 3](#pone.0125818.t003){ref-type="table"} shows the univariate and multivariate analyses of risk factors associated with one-year mortality. Using the group of patients with MR-CoNS IE with vancomycin MICs \<2 μg/mL treated with vancomycin (Group 2) as the reference, Group 1 (MS-CoNS IE treated with cloxacillin) and Group 3 (MR-CoNS IE with vancomycin MICs ≥2 μg/mL) respectively had independently lower and higher mortality (OR 0.12, 95% CI 0.02--0.55 and OR 3.7, 95% CI 0.9--15.2, respectively). Other independent variables associated with in-hospital mortality were heart failure and pacemaker lead endocarditis as a protective factor for mortality.

10.1371/journal.pone.0125818.t003

###### Prognostic factors associated with one-year mortality in the 85 patients of CoNS endocarditis treated with either cloxacillin or vancomycin.
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                                                            Univariate analysis                                   Multivariate analysis                                               
  --------------------------------------------------------- ----------------------------------------------------- ----------------------- ------------- --------- ------ ------------ -------
  Mean age (SD), y                                                                                                63.5 (14.3)             62.6 (16.1)   0.795                         
  Male gender                                                                                                     25 (74)                 40 (78)       0.602                         
  Year of diagnosis                                                                                                                                     0.929                         
                                                            1995                                                  11 (32)                 16 (31)                                     
                                                            2000                                                  12 (35)                 20 (39)                                     
                                                            2005                                                  11 (32)                 15 (29)                                     
  CoNS species                                                                                                                                          0.773                         
                                                            *S*. *epidermidis*                                    22 (65)                 35 (69)                                     
                                                            *S*. *lugdunensis*                                    6 (18)                  5 (10)                                      
                                                            Other species[^a^](#t003fn002){ref-type="table-fn"}   4 (12)                  7 (14)                                      
                                                            Polymicrobial                                         2 (6)                   4 (8)                                       
  Predisposing conditions and underlying diseases                                                                                                                                     
                                                            Diabetes mellitus                                     5 (15)                  5 (10)        0.733                         
                                                            Chronic renal failure                                 4 (12)                  2 (4)         0.212                         
                                                            Hemodialysis                                          1 (3)                   2 (4)         1.000                         
                                                            History of cancer                                     3 (9)                   6 (12)        0.735                         
                                                            HIV infection                                         1 (3)                   0             0.400                         
                                                            Chronic liver disease                                 8 (24)                  3 (6)         0.023                         
                                                            Chronic lung disease                                  1 (3)                   3 (6)         0.647                         
                                                            Transplantation                                       0                       1 (2)         1.000                         
                                                            History of IE                                         1 (3)                   1 (2)         1.000                         
  Presumed mode of acquisition                                                                                                                          0.619                         
                                                            Nosocomial                                            8 (24)                  10 (20)                                     
                                                            Non-nosocomial healthcare associated                  13 (38)                 16 (31)                                     
                                                            Community acquired                                    13 (38)                 25 (49)                                     
  Type of endocarditis                                                                                                                                                                
                                                            NV                                                    19 (56)                 9 (18)        \<0.001   0.1    0.02--0.51   0.006
                                                            PV                                                    13 (38)                 11 (22)       0.094                         
                                                            Pacemaker lead                                        2 (6)                   31 (61)       \<0.001                       
  Valve involvement                                                                                                                                                                   
                                                            Aortic                                                22 (65)                 12 (24)       \<0.001                       
                                                            Mitral                                                15 (44)                 11 (22)       0.027                         
                                                            ≥2 valves                                             8 (24)                  3 (6)         0.023                         
  Complications                                                                                                                                                                       
                                                            Heart failure                                         18 (53)                 5 (10)        \<0.001   6.2    1.5--25.2    0.011
                                                            Renal failure                                         21 (62)                 14 (28)       0.002                         
                                                            Systemic emboli                                       3 (9)                   5 (10)        1.000                         
                                                            Perivalvular abscess                                  10 (29)                 5 (10)        0.020                         
  Surgical treatment                                                                                              16 (47)                 40 (78)       0.003                         
  Treatment groups [^b^](#t003fn003){ref-type="table-fn"}                                                                                               0.003                         
                                                            Cloxacillin                                           8 (24)                  30 (59)                 0.12   0.02--0.55   0.008
                                                            Vancomycin (MIC \<2 μg/mL)                            13 (38)                 14 (27)                 1.0                 
                                                            Vancomycin (MIC ≥2 μg/mL)                             13 (38)                 7 (14)                  3.7    0.9--15.2    0.069

Unless otherwise noted, all values are shown as n (%). Abbreviations: CI, confidence interval; CoNS, coagulase-negative staphylococci; HIV, human immunodeficiency virus; IE, infective endocarditis; MIC, minimum inhibitory concentration; NV, native valve; OR, odds ratio; PV, prosthetic valve; SD, standard deviation.

^a^ *S*. *hominis* (7), *S*. *capitis* (2), *S*. *schleiferi* (2).

^b^In the multivariable regression analysis, cloxacillin treatment is the reference category. Vancomycin MIC \<2 μg/mL effect on one-year mortality is compared to cloxacillin and Vancomycin MIC ≥2 μg/mL is compared to Vancomycin MIC \<2 μg/mL.

Discussion {#sec010}
==========

Incidence, Types of IE, and Clinical Characteristics {#sec011}
----------------------------------------------------

CoNS are increasingly identified as a cause of NVE \[[@pone.0125818.ref008], [@pone.0125818.ref021]\] and caused 9% of all NVE in our cohort. In one recent multicenter investigation, nearly 8% of all NVE not associated with intravenous drug use (IVDU) were caused by CoNS, predominantly *S*. *epidermidis* \[[@pone.0125818.ref008]\]. A recent multinational prospective cohort study found that 16% of PVE not due to IVDU was attributed to CoNS \[[@pone.0125818.ref006]\]. *S*. *epidermidis* was isolated in 82% of cases, and 67% of these were methicillin-resistant. These results are similar to those seen in our series. In recent data provided by the International Collaboration on Endocarditis (ICE), CoNS was shown to be the second global cause of ICD IE immediately after *S*. *aureus*, being more often nosocomially-acquired than *S*.*aureus* \[[@pone.0125818.ref018]\].

Overall, we noted 44% of CoNS isolates were methicillin-resistant, a lower rate than documented in other surveys \[[@pone.0125818.ref019]--[@pone.0125818.ref022]\], and we did not find an association between methicillin-resistance and healthcare acquisition as did previous studies \[[@pone.0125818.ref008], [@pone.0125818.ref021]\]. Reduced susceptibility to vancomycin (MIC \>2 μg/mL) was found in 3% of CoNS isolates in our study, similar to a 2% rate in a recent review of bloodstream infections caused by CoNS \[[@pone.0125818.ref023]\]. As was the case with other recent summaries of susceptibility data from Spain \[[@pone.0125818.ref020]--[@pone.0125818.ref022]\], no CoNS isolates were resistant to vancomycin, linezolid, or daptomycin.

Impact of Oxacillin Susceptibility and Vancomycin MIC on Outcome {#sec012}
----------------------------------------------------------------

Vancomycin treatment was associated with higher mortality, especially among patients with IE due to isolates with vancomycin MICs ≥2 μg/mL. A number of studies have found a correlation between vancomycin MIC and poorer outcomes among patients with methicillin-resistant *S*. *aureus* bacteremia \[[@pone.0125818.ref024]\]. The present study is, to our knowledge, the first to demonstrate the same correlation between poor outcomes and vancomycin MIC in CoNS IE. This finding could have important clinical implications In addition, it suggests an important role for alternative antibacterial agents. In our series, higher vancomycin MICs had no impact on outcomes in patients with MS-CoNS IE receiving cloxacillin. In contrast, a recent study showed that among patients with methicillin-susceptible *S*. *aureus* (MSSA) bacteremia treated with flucloxacillin, outcomes were less favourable among those with higher vancomycin MICs \[[@pone.0125818.ref025]\]. Our group recently found the same association of high vancomycin MIC and left-sidedMSSA IE \[[@pone.0125818.ref026]\]. Higher vancomycin MICs could be a marker of bad prognosis in *S*. *aureus* bacteremia and IE regardless of the administered treatment, with the causative mechanism yet to be identified, but in light of our results, however, we cannot conclude that this hypothetical mechanism is common to all staphylococci.

Impact of Antibiotic Treatment on Outcome {#sec013}
-----------------------------------------

Vancomycin monotherapy is the treatment of choice for MR-CoNS NVE \[[@pone.0125818.ref010],[@pone.0125818.ref027]\]. However, we found very high mortality rates in vancomycin-treated patients. A vancomycin trough of 15--20 μg/mL is supposed to achieve the suggested target AUC/MIC ratios of ≥400 for organisms with MICs ≤1 μg/mL \[[@pone.0125818.ref028]\]. For patients infected with CoNS isolates having MICs ≥2 μg/mL, this ratio was likely not achieved in most cases; this may explain why patients with MR-CoNS IE with vancomycin MIC ≥2 μg/mL had the highest mortality rates. At the time the AHA guidelines were published, higher vancomycin troughs were not yet recommended and so were not targeted in our patients. Nonetheless, Holmes et al \[[@pone.0125818.ref029]\] did not clearly find better outcomes in patients with *S*. *aureus* bacteremia achieving an AUC/MIC ratio \>400. Thus, given these recent data and a lack of evidence regarding a correlation between AUC/MIC and CoNS bacteremia/IE outcomes, our results suggest the use of alternative agents to vancomycin.

For cases of MR-CoNS PVE, the recommended therapy is vancomycin in combination with rifampin and gentamicin \[[@pone.0125818.ref010],[@pone.0125818.ref027]\]. Interestingly, we found that 45% of the CoNS causing PVE were resistant to at least one recommended drug associated to vancomycin (data not shown). Thus, in our setting, it may not be unusual that empirical treatment for CoNS-PVE is inappropriate. Therefore, better antibiotic options are needed for CoNS PVE since deciding the most suitable combination for CoNS PVE may result challenging in light of current evidence. Although clinical data supporting the use of ceftaroline for CoNS IE is lacking, some *in vitro* studies provide interesting results, showing a good susceptibility profile for ceftaroline against CoNS that includes methicillin-resistant, linezolid-resistant and daptomycin non-susceptible strains \[[@pone.0125818.ref030],[@pone.0125818.ref031]\]. Besides, no emergence of ceftaroline-resistant strains has been described to date. Clinical evidence also lacks for telavancin, whose *in vitro* activity against CoNS is better than vancomycin due to its dual mechanism of action, which confers a rapid bactericidal activity \[[@pone.0125818.ref032], [@pone.0125818.ref033]\]. However, increased MICs for telavancin have been reported in some strains of *S*. *epidermidis* with reduced susceptibility to glycopeptides \[[@pone.0125818.ref033]\]. As occurred with the former agent, no clinical experience with tigecycline for the treatment of CoNS IE is yet available and experimental evidence from the IE model has been neither published. Linezolid use is limited in monotherapy due to its bacteriostatic activity. Noteworthy, emergence of resistance to linezolid among CoNS is increasingly reported \[[@pone.0125818.ref034]\]. Results derived from both *in vivo* studies and clinical experience with daptomycin are encouraging \[[@pone.0125818.ref035]--[@pone.0125818.ref038]\]. We have previously shown in animal models that daptomycin was a better therapeutic option than vancomycin \[[@pone.0125818.ref035], [@pone.0125818.ref039]\], particularly for IE caused by MR-CoNS with vancomycin MICs \>1 μg/mL. Consequently, we believe that daptomycin should be considered as the preferred alternative for patients with NVE or PVE caused by MR-CoNS.

Study Limitations {#sec014}
-----------------

This study has several limitations. First, it is a non-randomized, observational study. Second, it was conducted at a single, tertiary referral center for IE, so referral bias limits external validity, as does the loss of some of the isolates of transferred patients. Third, while the total number of IE cases diagnosed in our center is large, the number of documented CoNS cases is relatively small and did not allow us to investigate the impact of vancomycin MIC in subpopulations of interest (eg, at the species level, according to IE type). As stated above, our study lacks pharmacokinetic and pharmacodynamic data, especially regarding the assessment of AUC/MIC ratios.

Conclusion {#sec015}
==========

CoNS are well recognized as an important cause of IE, including infections of both native and prosthetic valves, as well as those involving pacemakers. Such infections are often acquired in healthcare settings, and are caused increasingly by pathogens less susceptible to agents like vancomycin that have long been standards of care. While several studies have documented poor outcomes among vancomycin-treated patients with serious *S*. *aureus* infections caused by isolates with higher vancomycin MICs, our report is the first to demonstrate a similar pattern among patients with MR-CoNS IE. Alternatives to currently recommended drugs should be considered in future studies. So, additional randomized, controlled studies are warranted.

Supporting Information {#sec016}
======================

###### Clinical characteristics and outcomes of 88 patients with IE due to CoNS, according to the CoNS species.
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###### Activity of 11 selected antibiotics as determined by Etest for 98 CoNS isolates from 88 patients with IE.
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###### Basal characteristics, microbiological features and outcome of the 39 patients with CoNS strains with vancomycin ≥2 μg/mL.
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